β‐Herpesvirus Challenges in the Transplant Recipient
Open Access
- 15 October 2002
- journal article
- review article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 186 (s1) , S99-S109
- https://doi.org/10.1086/342962
Abstract
Cytomegalovirus (CMV) has major consequences after allogeneic stem cell and solid organ transplantation. CMV may cause significant morbidity and mortKeywords
This publication has 107 references indexed in Scilit:
- High levels of human herpesvirus 6 DNA in peripheral blood leucocytes are correlated to platelet engraftment and disease in allogeneic stem cell transplant patientsBritish Journal of Haematology, 2000
- High‐dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patientsTransplant Infectious Disease, 1999
- Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal TransplantationNew England Journal of Medicine, 1999
- Pharmacokinetics of Valganciclovir and Ganciclovir Following Multiple Oral Dosages of Valganciclovir in HIV- and CMV-Seropositive VolunteersClinical Pharmacokinetics, 1999
- Editorial Response: Cytomegalovirus Disease and Allograft Loss After Organ TransplantationClinical Infectious Diseases, 1998
- Genetic content of a 20.9 kb segment of human herpesvirus 6B strain Z29 spanning the homologs of human herpesvirus 6A genes U40—57 and containing the origin of DNA replicationArchiv für die gesamte Virusforschung, 1997
- OKT3 Treatment for Allograft Rejection Is a Risk Factor for Cytomegalovirus Disease in Liver TransplantationThe Journal of Infectious Diseases, 1995
- CYTOMEGALOVIRUS PNEUMONIA AFTER BONE MARROW TRANSPLANTATIONTransplantation, 1993
- A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal AllograftsNew England Journal of Medicine, 1989
- Acyclovir for Prevention of Cytomegalovirus Infection and Disease after Allogeneic Marrow TransplantationNew England Journal of Medicine, 1988